In an insightful meta-analysis, Fan K and collaborators demonstrated that elevated EZH2 expression correlates with poor prognosis and supports the survival of dormant cells in both NSCLC and SCLC [60]. Here, EZH2 is linked to non-small cell lung carcinoma.